These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 15073105)

  • 1. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
    Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
    Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells.
    Squires MS; Hudson EA; Howells L; Sale S; Houghton CE; Jones JL; Fox LH; Dickens M; Prigent SA; Manson MM
    Biochem Pharmacol; 2003 Feb; 65(3):361-76. PubMed ID: 12527329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
    Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
    Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
    Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
    Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravitreal insulin and insulin signaling cascade inhibitors on emmetropization in the chick.
    Penha AM; Burkhardt E; Schaeffel F; Feldkaemper MP
    Mol Vis; 2012; 18():2608-22. PubMed ID: 23112573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways.
    Subramaniam S; Strelau J; Unsicker K
    J Biol Chem; 2003 Mar; 278(11):8904-12. PubMed ID: 12514175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
    Baker CH; Solorzano CC; Fidler IJ
    Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
    Holcomb B; Yip-Schneider MT; Matos JM; Dixon J; Kennard J; Mahomed J; Shanmugam R; Sebolt-Leopold J; Schmidt CM
    J Gastrointest Surg; 2008 Feb; 12(2):288-96. PubMed ID: 18049840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway.
    Qiao M; Shapiro P; Kumar R; Passaniti A
    J Biol Chem; 2004 Oct; 279(41):42709-18. PubMed ID: 15304489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
    Ng SSW ; Tsao MS; Chow S; Hedley DW
    Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
    Li J; Liang X; Yang X
    Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways.
    Qiu Q; Yang M; Tsang BK; Gruslin A
    Reproduction; 2004 Sep; 128(3):355-63. PubMed ID: 15333786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
    Bruns CJ; Solorzano CC; Harbison MT; Ozawa S; Tsan R; Fan D; Abbruzzese J; Traxler P; Buchdunger E; Radinsky R; Fidler IJ
    Cancer Res; 2000 Jun; 60(11):2926-35. PubMed ID: 10850439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition.
    Nelson JM; Fry DW
    J Biol Chem; 2001 May; 276(18):14842-7. PubMed ID: 11278435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT; Schmidt CM
    Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
    Fryer RA; Barlett B; Galustian C; Dalgleish AG
    Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.